Cancer Genetics, Inc. (CGIX), an emerging leader in DNA-based cancer diagnostics, Monday announced the signing of a definitive agreement to acquire privately held Gentris Corp., a provider of clinical pharmacogenomics solutions, next-generation sequencing, and biomarker testing.
Cancer Genetics said it expects the acquisition to add approximately $5 to $6 million in annual sales, and add substantially to it biopharma revenue backlog and capabilities.
Gentris provides genomic testing and pharmacogenomics services and has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China.
With the deal, the company said it will now be positioned to provide global services for genomic and biomarker testing for biotech and pharmaceutical companies by leveraging both it's unique tests and comprehensive oncology services.
For comments and feedback contact: editorial@rttnews.com
Business News